about
Polyethylene Glycol Preconditioning: An Effective Strategy to Prevent Liver Ischemia Reperfusion Injury.A protein engineering approach differentiates the functional importance of carbohydrate moieties of interleukin-5 receptor αPEGylation, successful approach to drug deliveryPeritoneal tumor carcinomatosis: pharmacological targeting with hyaluronan-based bioconjugates overcomes therapeutic indications of current drugsSite-specific pegylation of G-CSF by reversible denaturation.A new method to increase selectivity of transglutaminase mediated PEGylation of salmon calcitonin and human growth hormone.Selective conjugation of poly(2-ethyl 2-oxazoline) to granulocyte colony stimulating factor.Novel monodisperse PEG-dendrons as new tools for targeted drug delivery: synthesis, characterization and cellular uptake.Polyethylene glycol rinse solution: an effective way to prevent ischemia-reperfusion injuryRole of proton pump inhibitor on esophageal carcinogenesis and pancreatic acinar cell metaplasia development: an experimental in vivo studyAnti-cancer PEG-enzymes: 30 years old, but still a current approach.PEG conjugates in clinical development or use as anticancer agents: an overview.State of the art in PEGylation: the great versatility achieved after forty years of research.Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol.Enzymatic formation of PEGylated oligonucleotides.Thiol-Activated Anticancer Agents: The State of the Art.A hyaluronic acid-salmon calcitonin conjugate for the local treatment of osteoarthritis: chondro-protective effect in a rabbit model of early OA.Poly(ethylene glycol)-paclitaxel-alendronate self-assembled micelles for the targeted treatment of breast cancer bone metastases.Dendritic poly(ethylene glycol) bearing paclitaxel and alendronate for targeting bone neoplasms.Relevance of folic acid/polymer ratio in targeted PEG-epirubicin conjugates.Polymer-drug conjugates for combination anticancer therapy: investigating the mechanism of action.Poly(ethylene glycol)-mesalazine conjugate for colon specific delivery.Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid.Cardiac safety and antitumoral activity of a new nitric oxide derivative of pegylated epirubicin in mice.PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity.Poly(ethylene glycol)-poly(ester-carbonate) block copolymers carrying PEG-peptidyl-doxorubicin pendant side chains: synthesis and evaluation as anticancer conjugates.Site-Specific Transglutaminase-Mediated Conjugation of Interferon α-2b at Glutamine or Lysine Residues.A site-selective hyaluronan-interferonα2a conjugate for the treatment of ovarian cancer.PHEA-graft-polymethacrylate supramolecular aggregates for protein oral delivery.Detection of sites of infection in mice using 99mTc-labeled PN(2)S-PEG conjugated to UBI and 99mTc-UBI: a comparative biodistribution study.Synthesis, characterization and preliminary cytotoxicity assays of poly(ethylene glycol)-malonato-Pt-DACH conjugates.Highly efficient technetium-99m labeling procedure based on the conjugation of N-[N-(3-diphenylphosphinopropionyl)glycyl]cysteine ligand with poly(ethylene glycol).A new PEG-beta-alanine active derivative for releasable protein conjugation.Synthesis and characterization of poly(2-ethyl 2-oxazoline)-conjugates with proteins and drugs: suitable alternatives to PEG-conjugates?Polyethylene glycol (PEG)-dendron phospholipids as innovative constructs for the preparation of super stealth liposomes for anticancer therapy.Transgultaminase-Mediated Nanoarmoring of Enzymes by PEGylation.Kinetic interaction analysis of human interleukin 5 receptor alpha mutants reveals a unique binding topology and charge distribution for cytokine recognition.Polyethylene glycol and a novel developed polyethylene glycol-nitric oxide normalize arteriolar response and oxidative stress in ischemia-reperfusion.Cisplatin liposome and 6-amino nicotinamide combination to overcome drug resistance in ovarian cancer cells.Transglutaminase and Sialyltransferase Enzymatic Approaches for Polymer Conjugation to Proteins.
P50
Q27348973-CFEC9846-39B0-46A3-A51E-7A125443233DQ28243627-87A8DE07-C03C-41BC-9B18-AF0D619BEC35Q28278538-6982674A-CA29-483D-96B6-C144B4E603F0Q28544821-6FD2BD1A-D98D-4B6B-A51D-5CD3A54E0ED7Q33302930-4E8B8BDD-0070-45C3-B534-8478CDFE0D29Q33897471-57E58A35-9318-4EAC-BCCE-F7EB5BDC796AQ34190524-45A87352-47C9-46C2-B3D7-8EFC6B9BEDDCQ34482408-D0C2E16F-1399-424A-8B93-1C0F542A7AD2Q34552111-EA362ACB-B142-4D03-8577-733F58BE7A5AQ35441801-3D9AE21A-1EE3-4A6F-B01F-BC29521EBD22Q36942372-29F63BED-E19C-421A-95C9-8BA0688D55A1Q37578051-4094CB20-9AB6-449B-BDAF-680EA5D5C991Q37957484-125B95BA-BFEE-4D58-93D4-4FF14EE96124Q38200926-38821F32-1E23-459F-AF9C-7ABB80F096AAQ38309559-F96EBDED-5B4E-4B92-A7BF-311CBA744A96Q38931329-659864F7-1C92-4CCF-A481-B8A642DBE6DFQ38994185-B39A3925-27BA-49EC-A56B-82AA79A0776BQ39189969-55E8BFBA-3C2A-4F02-9F88-181589EC4859Q39537304-9D33090A-2E6B-401A-A926-5E7CBF3572F1Q39681805-DD518D6B-1822-4602-9EE9-B34E3B56A9DDQ39797852-3CE799CA-4F16-4588-82A4-5DF127D318AEQ39919614-4EA428F4-0C57-4A0F-9DC8-33951FB91590Q40001636-B51E7B94-2EA4-4D80-B5CD-B8D080DAA681Q40092636-8676FE40-D27F-438F-9288-5AD5B1B37C80Q40395925-86D59098-7FC4-48DA-B727-FBA9676AADE4Q40447780-3D4C1324-96C9-48AE-9D65-6FD88BD6E8EAQ40509438-2458566D-067A-4164-AD4C-D54EC6B196CDQ40676079-CF7D753F-701E-4103-A518-015EA42531D4Q42518431-52E8972F-425E-4FAB-8568-5B0C42DD40F3Q44470639-56730258-94F1-47BB-9545-77ADDD1D1E33Q44559006-6AD0EFF7-8FF0-4B49-A32F-38FE3A1A29F9Q45058676-063C8CEA-489F-45B7-AACA-E35BD714BF8DQ46216600-CAC95792-AA82-47F1-9BAC-DBE2F050A73CQ46887032-7AD9DF3F-84A5-40EA-9054-EF06145383D5Q50615834-1F370AD9-4234-4116-93EA-F7CBBAA5053EQ51057044-296BE6D0-A820-4FE3-80C3-03718C2C5390Q51598582-67C14DDC-4D63-4114-B325-CAB6418ABB51Q51810070-2484AFDC-5A74-4DDC-9CC3-DD06B99EBE5BQ52571253-634A7453-8743-4EAE-895E-876F4A1040F1Q52572533-3C9BA81A-8510-442D-9898-AD4359F48CC4
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Gianfranco Pasut
@ast
Gianfranco Pasut
@en
Gianfranco Pasut
@es
Gianfranco Pasut
@nl
Gianfranco Pasut
@sl
type
label
Gianfranco Pasut
@ast
Gianfranco Pasut
@en
Gianfranco Pasut
@es
Gianfranco Pasut
@nl
Gianfranco Pasut
@sl
prefLabel
Gianfranco Pasut
@ast
Gianfranco Pasut
@en
Gianfranco Pasut
@es
Gianfranco Pasut
@nl
Gianfranco Pasut
@sl
P106
P21
P31
P496
0000-0002-8754-0899